Results 301 to 310 of about 1,467,646 (404)

Targeted Penetrating Motif Engineering of BH3 Mimetic: Harnessing Non‐Canonical Amino Acids for Coinhibition of MCL‐1 and BCL‐xL in Acute Myeloid Leukemia

Advanced Science, Volume 12, Issue 27, July 17, 2025.
A structure‐guided peptide derived from a non‐canonical amino acid library simultaneously targets MCL‐1 and BCL‐xL to overcome apoptotic resistance in acute myeloid leukemia. Fused with a CXCR4‐binding motif, the engineered peptide exhibits selective intracellular delivery and potent in vivo efficacy, offering a promising therapeutic strategy against ...
Zhe Wang, Ruizhi Lai, Xinpei Wang, Xu Chen, Youjian Zhou, Shengbin Li, Xiaohui Qiu, Zekai Zeng, Jianye Yuan, Jinghuan Mao, Zhidong Chen, Junqing Wang   +11 more
wiley   +1 more source

Disparities in Clinical Trial Enrollment- Focus on CAR-T and Bispecific Antibody Therapies. [PDF]

Curr Hematol Malig Rep
Islam N, Budvytyte L, Khera N, Hilal T.
europepmc   +1 more source

Development of a T cell engaging bispecific antibody targeting long non-coding RNA PVT1. [PDF]

Cancer Immunol Immunother
Kato H, Tsukahara T, Murata K, Nishikata H, Mizue Y, Sasaya T, Kubo T, Kanaseki T, Hirohashi Y, Oyagi A, Maeda T, Miyazaki A, Torigoe T.   +12 more
europepmc   +1 more source

Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.

Blood
Tumuluru S, Godfrey JK, Cooper A, Yu J, Chen X, MacNabb BW, Venkataraman G, Zha Y, Pelzer B, Song J, Duns G, Sworder BJ, Raj S, Bolen C, Penuel E, Postovalova E, Kotlov N, Bagaev A, Fowler N, Shouval R, Smith SM, Alizadeh AA, Steidl C, Kline J.   +23 more
europepmc   +1 more source

Improving CD3 bispecific antibody therapy in solid tumors using combination strategies. [PDF]

Front Oncol
Lloyd K, Middelburg J, Ovcinnikovs V, Pencheva N, Kemper K, van Hall T.   +5 more
europepmc   +1 more source

Midkine Promotes Tumor Growth and Attenuates the Effect of Cisplatin in Small Cell Lung Cancer

Cancer Medicine, Volume 14, Issue 13, July 2025.
ABSTRACT Purpose Small cell lung cancer (SCLC) is a highly aggressive disease associated with poor patient survival rates. The addition of an anti‐programmed death ligand 1 antibody to platinum combination chemotherapy can improve its prognosis. However, only a few patients achieve a long‐term response; thus, establishing new therapies for SCLC is ...
Shotaro Ito, Jun Sakakibara‐Konishi, Mineyoshi Sato, Tetsuaki Shoji, Megumi Furuta, Hirofumi Takahashi, Kosuke Tsuji, Daisuke Morinaga, Masahiro Kashima, Hidenori Kitai, Junko Kikuchi, Eiki Kikuchi, Kanako C. Hatanaka, Yutaka Hatanaka, Kyoko Hida, Takuro Noguchi, Satoshi Konno   +16 more
wiley   +1 more source

Camelid immunoglobulins and nanobody technology [PDF]

, 2009
Baral, TN, De Baetselier, P, De Genst, E, Hassanzadeh-Ghassabeh, G, Kinne, J, Leonhardt, H, Magez, Stefan, Muyldermans, S, Nguyen, VK, Retarnozzo, VC, Revets, H, Rothbauer, U, Saerens, D, Stijemans, B, Tillib, S, Wernery, U, Wyns, L   +16 more
core   +1 more source

Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes

Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 74-79, July 2025.
Oncology dose optimization during the era of chemotherapy focused on identifying the maximum tolerated dose (MTD) for registrational trials, often resulting in significant toxicity. The advent of molecular targeted drugs and immunotherapies offers the potential to achieve similar efficacy with lower doses and fewer side effects, as maximal efficacy is ...
Jiawen Zhu, Amy Schroeder, Sabine Frank, Christophe Boetsch, Candice Jamois, Nastya Kassir, Koorosh Korfi, Elizabeth Punnoose, Anjali Vaze, Peter Trask, Pritti Gosai, Jane Fridlyand, Chunze Li   +12 more
wiley   +1 more source

Predicting bispecific antibody failure in diffuse large B-cell lymphoma. [PDF]

Hematology Am Soc Hematol Educ Program
Barraclough A, Hawkes EA.
europepmc   +1 more source

CD70: An emerging target for integrated cancer diagnosis and therapy

Clinical and Translational Medicine, Volume 15, Issue 7, July 2025.
CD70 is aberrantly overexpressed in diverse tumours with limited normal tissue expression, making it a compelling diagnostic and therapeutic target. Immuno‐PET/CT facilitates tumour detection, staging, and treatment monitoring. Multiple CD70‐targeted therapies are under early evaluation. Rational combination strategies are emerging to enhance antitumor
Jiatao Hu, Jinxin Li, Bo Yang, Siyi Wang, Yi Bao, Yiren Yang, Kun Qiao, Fei Guo, Xinxin Gan, Linhui Wang   +9 more
wiley   +1 more source